[1] [2] In the UK, according to their Summary of Product Characteristics (SmPCs), these medications are licensed for adults with a body mass index (BMI) of 30 kg/m or above, or 27 kg/m or above in the presence of weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea
OPINION: Childhood obesity gets a prescriptionand the food sector a warning Fifty-eight per cent of people taking or considering taking GLP-1 drugs said weight loss was their main driver, while 42% said diabetes was their primary reason
This fundamental difference introduces a degree of uncertainty that is incompatible with safe medical care
If you continue to experience side effects or find that they worsen, tell your healthcare provider so they can adjust your treatment accordingly
Citibank also offers 60,000+ fee-free ATMs (vs